Veltek Associates, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Veltek Associates, Inc. (VAI) provides innovative solutions to address the control of particulate and microbial contamination in pharmaceutical and biotechnology operations worldwide.  We focus on the identification and control of contamination in classified areas.

VAI’s Sterile Chemical Manufacturing Division (SCMD) produces a complete range of sterile disinfectants, sanitizers, sporicides, lubricants, cleaners, detergents (CIP), and buffer solutions.  We offer hand sanitizers and hands-free dispensing systems in addition to developing the Core2Clean Plus System that can spray, mop or fog in one device.   

VAI’s Environmental Control Monitoring Division (ECMD) designs an assortment of viable air sampling equipment.  This product line includes portable devices, compressed air sampling, and facility wide monitoring systems with numerous possibilities to maximize the use of EM information.

VAI’s Disposable Products Manufacturing Division (DPMD) offers sterile cleanroom garments, face masks and nylon packaging material.  These garments also come in a patented fold (Easy2Gown) that makes gowning simple and easy for your operators.



VAI Labs provides microbiological testing ranging from the identification of microorganisms to antimicrobial effectiveness studies, a disinfectant validation service. 

Aseptic Processing Inc. (consulting) provides consulting services in aseptic technique, environmental monitoring, component entry systems, personnel gowning, cleaning and disinfecting systems, and media fill trials.

Veltek Associates, Inc.
www.sterile.com
vai@sterile.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here